2009

This year Alvogen was founded on the strong foundation of Norwich Pharmaceutical Services, with a 125-year history.

Alvogen brand is introduced

New business model is launched.

Robert Wessman joins Alvogen as Chairman and CEO

Alvogen acquires R&D capabilities

Alvogen acquired research and development capabilities from Par Pharmaceutical.

Alvogen Launches Asia Operations

2010

International expansion started. Foundation laid in major fields of operation.

Expansion in Eastern Europe

Alvogen expands operations in Eastern Europe and opens an office in Bucharest, Romania.

Top executives appointed

Alvogen’s leadership team is dedicated to fostering a dynamic change-driven culture committed to meeting the needs of our customers.

Alvogen expands its operations in India

R&D center opens in Pinebrook, NJ

Alvogen acquires Keri Pharma

Alvogen gains access to an important pharmaceutical market in Hungary.

Alvogen teams up with Orchid in India

The partnership further strengthens Alvogen's product pipeline in the US.

2011

International expansion continues. First products sold in the U.S. market.

First product launches in Thailand market

First-to-file-on Tamiflu

Alvogen and Natco secure first-to-file status on generic version of Tamiflu. 

Alvogen opens new offices including Poland, Russia, Croatia, Macedonia, Albania and Kazakhstan

U.S. team hits record in sales

A record was set in increased sales in the month of September on the US market.

New OTC line launched in China

 Alvogen launched a new OTC product line in China under the brand name Pure Iceland.

NCS inaugurates a new clinical facility in India

Norwich Clinical Services (NCS) in India, has inaugurated a new, 72-bed clinical facility in Bangalore, India.

MIT and Columbia

Academic partnerships with MIT and Columbia University.

2012

Alvogen enters the APAC region through strategic acquisitions. Biosimilar partnership signed with Hospira.

Packaging center in Serbia

Packaging centre built in Serbia serving the entire CEE region.

Biosimilar partnership

Biosimilar partnership signed with Hospira, first biosimilars sold in CEE.

CRO built in Bangalore

First products launched in APAC

First generic products sold in the APAC market.

Alvogen U.S. received Diana Merit Award

Alvogen aquires majority in Kunwha

Alvogen acquires majority of shares in the Korean Kunwha Pharmaceuticals to establish a local development, manufacturing and marketing platform in the Asia-Pacific region.

Norwich pharmaceuticals received CMO Leadership Award

The Award are granted for the areas of Quality, Innovation, Productivity, Regulatory, and Reliability.

2013

Alvogen recognized for a dynamic growth in the US market and further steps taken in the development of the APAC platform.

Diana Award received

CMO Leadership Award

Alvogen received CMO Leadership Awards for the second year running.

Acquisitions of Labormed in Romania

Alvogen acquires Naprelan® in the US

Alvogen Pharma U.S. finalized a transaction with Shionogi Inc., acquiring the exclusive right to commercialize NAPRELAN® 

Groundbreaking of a new biopharmaceuticals plant

Alvogen and Lotus merge Asian operations

Alvogen becomes the majority shareholder in Taiwanese Lotus Pharmaceuticals.

2014

Biosimilar platform strengthened with new monoclonal antibodies launched in the CEE region. Alvogen acquires Korean Dream Pharma.

First-to-market with Inflectra in Europe with Hospira

Inflectra is the first biosimilar monoclonal antibodies to be approved in Europe.

Alvogen scores high at CPHI 2014 for the third year in a row

Alvogen wins DIANA “Oscar” for the third consecutive year

Alvogen U.S. was this year’s recipient of HDMA’s Distribution Industry Award for Notable Achievement in Healthcare in the category of Best Overall Generic Pharmaceutical Manufacturer with sales to Healthcare Distributors. 

Alvogen receives double Awards from the Generics Bulletin

Pamplona acquires stake in Alvogen

Pamplona Capital Management, an international private equity company, acquired a majority stake in Alvogens business from legacy shareholders.

Alvogen acquires Korean Dream Pharma

2015

Strategic launches, prestigious consortium of new investors on board and Asian operations strengthened.

Dream Pharma and Kunwha pharmaceuticals become Alvogen Korea

First Merit at DIANA Awards

Alvogen was honored as a "Generic Pharmaceutical Product Manufacturer with Sales to Healthcare Distributors."

Alvogen launches

the first generic  Exelon® patch in the United states

CVC Capital Partners leads investment consortium to acquire controlling stake in Alvogen

Alvogen won EMEA company of the year awards from Generics Bulletin

2016

Alvogen Kicks Off in Thailand

Alvogen held its annual Kick-off in Phuket, Thailand. 115 company executives attended to discuss strategies and objectives.

Alvogen expands US business

Agreement signed to acquire County Line Pharmaceuticals

ALVOGEN IN HARVARD CASE STUDY

ALVOTECH OPENS STATE-OF-THE-ART BIOSIMILAR FACILITY IN ICELAND

ALVOGEN LAUNCHES FIRST GENERIC EQUIVALENT OF COPAXONE(TM) IN EUROPE

Launch of Zoloadex

Alvogen announced the launch of the first generic equivalent of ZoladexTM in Central and Eastern Europe.

ALVOGEN LAUNCHES THE FIRST GENERIC EQUIVALENT TO TAMIFLU® CAPSULES IN THE UNITED STATES

2017

Alvogen Kicks Off in Malta

Global Kick-off in Malta